VP of Alliance Management & Portfolio Planning at Genentech to Give Plenary Keynote Address at 4th Modern Drug Discovery & Development Summit Oct. 15-17, 08 San Diego
Summary
He will assess the current environment for drug development and answer such questions as “Is innovation in the pharmaceutical industry threatened?” Finally, Dr. Hanna will outline possible trends to consider that we can impact to maintain a focus on scientific progress and improved treatments for patients.Other plenary speakers include John Doll, Commissioner of Patents at the US Patent & Trademark Office, David Nicholson, SVP of Global Project Management at Schering Plough, Keith James, SVP & Site Head at Pfizer La Jolla, Johan Luthman, Global Head of Exploratory Medicine Neurology at MerckSerono and Sandy Macrae, VP of Business Development at GlaxoSmithKline.The 6 tracks will cover Biological Therapeutics, Translational Medicine, Drug Design & Lead Optimization, Emerging Targets &, Pharmacokinetics & Pharmacodynamics and Partnering, Licensing & Outsourcing.Other plenary speakers include John Doll, Commissioner of Patents at the US Patent & Trademark Office, David Nicholson, SVP of Global Project Management at Schering Plough, Keith James, SVP & Site Head at Pfizer La Jolla, Johan Luthman, Global Head of Exploratory Medicine Neurology at MerckSerono and Sandy Macrae, VP of Business Development at GlaxoSmithKline.The 6 tracks will cover Biological Therapeutics, Translational Medicine, Drug Design & Lead Optimization, Emerging Targets &, Pharmacokinetics & Pharmacodynamics and Partnering, Licensing & Outsourcing.